Literature DB >> 16027400

Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations.

Pamala A Jacobson1, Kathleen G Green, Bernhard J Hering.   

Abstract

The authors investigated the pharmacokinetics of mycophenolic acid over 1 year in 8 Caucasian women undergoing islet cell transplantation. Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61). Median total trough concentrations were 1.16-2.90 mcg/mL. Unbound AUC(0-12) was 412-673 ng x h/mL and did not change over time (P = .30). Median percent unbound mycophenolic acid was 0.95% of total concentrations. Individual unbound and total mycophenolic acid concentrations were highly correlated (r2 = 0.94). Total mycophenolic acid trough concentration and total AUC(0-12) were modestly correlated (r2 = 0.65). Intra- and interpatient variability of systemic mycophenolic acid exposure was high. Six patients required dose reductions prior to day 60 due to adverse effects. All subjects achieved insulin independence; 3 later lost graft function. The trend toward higher exposure in the early periods followed by dose reductions suggests that lower initial doses and therapeutic drug monitoring may be necessary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027400     DOI: 10.1177/0091270005278599

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

1.  Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.

Authors:  L'aurelle A Johnson; William S Oetting; Saonli Basu; Susie Prausa; Arthur Matas; Pamala A Jacobson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-21       Impact factor: 2.953

2.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Authors:  Paul J Martin; Barry E Storer; Scott D Rowley; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; John R Wingard; Paul J Shaughnessy; Marcel P DeVetten; Madan Jagasia; Joseph W Fay; Koen van Besien; Vikas Gupta; Carrie Kitko; Laura J Johnston; Richard T Maziarz; Mukta Arora; Pamala A Jacobson; Daniel Weisdorf
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

3.  Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Pamala A Jacobson; Jiayin Huang; Juan Wu; Miae Kim; Brent Logan; Amin Alousi; Michael Grimley; Javier Bolaños-Meade; Vincent Ho; John E Levine; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-03       Impact factor: 5.742

4.  Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.

Authors:  P Jacobson; S F El-Massah; J Rogosheske; A Kerr; J Long-Boyle; T DeFor; C Jennissen; C Brunstein; J Wagner; M Tomblyn; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  2009-01-19       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.